Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Single-cell RNA sequencing (scRNA-seq) is vital for studying the tumor microenvironment (TME) and its response to immunotherapy.
• Predicting immunotherapy efficacy is a key challenge in current cancer research.
• Immune cell heterogeneity within the TME significantly impacts treatment outcomes.

Purpose of the Study:

• To review the current applications of scRNA-seq in immunotherapy research.
• To identify challenges and propose future directions for scRNA-seq in this field.
• To explore the integration of biomaterials with tumor immunotherapy.

Main Methods:

• Utilizing scRNA-seq to analyze immune cell heterogeneity in the TME.
• Investigating the impact of biomaterials on tumor immunotherapy through scRNA-seq.
• Systematic evaluation of TME modifications induced by biomaterials.

Main Results:

• scRNA-seq shows promise in predicting immunotherapy efficacy and discovering biomarkers.
• Demonstrates potential for systematic evaluation of biomaterial-induced TME changes.
• Highlights the complex role of immune cell heterogeneity in treatment response.

Conclusions:

• scRNA-seq is a powerful tool for advancing tumor immunotherapy research.
• Addressing current challenges will enhance the predictive power and biomarker discovery capabilities of scRNA-seq.
• Integrating biomaterials offers novel strategies for improving immunotherapy outcomes.